Uncategorised - European Medical Journal

Heart Attack Damage Driven by Natural Killer Cells

Genetic deletion or pharmacological depletion of NK cells reduced cardiomyocyte death, limited inflammation, and improved cardiac function.

Binge Drinking Once a Month May Triple Liver Fibrosis Risk

Patients with MASLD who binge drink, even once a month, face a threefold higher risk of advanced liver fibrosis.

ASCVD costs global health industry $680bn annually

Atherosclerotic cardiovascular disease costs the equivalent of Sweden’s entire economy, a new report has revealed.

New Risk Score Predicts Laryngeal Involvement in Pemphigus Vulgaris

Study introduces a clinical score to predict laryngeal involvement in pemphigus vulgaris, supporting targeted use of laryngoscopy.

Optimising Patient Outcomes in Advanced Gastrointestinal Stromal Tumours (GIST) in Europe

Corrigendum: Optimising Patient Outcomes in Advanced Gastrointestinal Stromal Tumours (GIST) in Europe

This infographic, which was originally published on 19.02.25, has been updated to provide a more simplified view of the ESMO EURACAN…

Reframing Vasoplegia in the ICU

Vasoplegia is defined as sustained low systemic vascular resistance in the context of a normal or high cardiac index, leading to…

Pancreatic Tumour Survival Prediction Model

A validated nomogram predicts survival in solid pseudopapillary neoplasm, showing strong accuracy and clinical utility across training, validation, and external cohorts.

GLP-1 Agonists Lower Complications and Mortality in Pancreatitis

A large multicentre study finds GLP-1 receptor agonists do not increase pancreatitis risk and are associated with fewer complications and lower mortality in Type 2 diabetes.

Ending HIV Testing May Raise Infections 10% by 2030

Ending CDC-funded HIV testing could raise infections by 10%, with rural areas most affected, highlighting the key role of early diagnosis.

Oncologist reviewing next-generation sequencing results and genomic testing data for a patient with advanced cancer.

Who Is Missing Out on Next-Generation Sequencing in Cancer?

Next-generation sequencing use rose in advanced cancer, but access remained uneven across socioeconomic, racial, and insurance groups.